Aciphex
NDC Package 62856-243-41
Package Information
Aciphex is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute Tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.3), Adverse Reactions (6)].PPIs, including ACIPHEX, are contraindicated with rilpivirine-containing products [see Drug Interactions (7)].For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX delayed-release tablets, refer to the Contraindications section of their package inserts. Marketed by Eisai Inc., this product is identified by NDC 62856-243 and is authorized under FDA application NDA020973.
Identification & Billing
- RxCUI: 854868 - RABEprazole sodium 20 MG Delayed Release Oral Tablet
- RxCUI: 854868 - rabeprazole sodium 20 MG Delayed Release Oral Tablet
- RxCUI: 854870 - AcipHex 20 MG Delayed Release Oral Tablet
- RxCUI: 854870 - rabeprazole sodium 20 MG Delayed Release Oral Tablet [Aciphex]
- RxCUI: 854870 - Aciphex 20 MG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62856 - Eisai Inc.
- 62856-243 - Aciphex
- 62856-243-41 - 100 BLISTER PACK in 1 CARTON / 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK
- 62856-243 - Aciphex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62856-243). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62856-243-41 identifies a specific commercial package of 100 blister pack in 1 carton / 1 tablet, delayed release in 1 blister pack of Aciphex, labeled by Eisai Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Eisai Inc. on August 19, 1999. The current certification is valid through December 31, 2023.
How is this Eisai Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62856024341. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.